Drug-induced Fatty Liver Disease: Pathogenesis and Treatment

Metabolic dysfunction-associated fatty liver disease (commonly known as MAFLD) impacts global health in epidemic proportions, and the resulting morbidity, mortality and economic burden is enormous. While much attention has been given to metabolic syndrome and obesity as offending factors, a growing...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical and translational hepatology 2021-09, Vol.9 (5), p.731-737
Main Authors: Kolaric, Tea Omanovic, Nincevic, Vjera, Kuna, Lucija, Duspara, Kristina, Bojanic, Kristina, Vukadin, Sonja, Raguz-Lucic, Nikola, Wu, George Y, Smolic, Martina
Format: Article
Language:English
Subjects:
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Metabolic dysfunction-associated fatty liver disease (commonly known as MAFLD) impacts global health in epidemic proportions, and the resulting morbidity, mortality and economic burden is enormous. While much attention has been given to metabolic syndrome and obesity as offending factors, a growing incidence of polypharmacy, especially in the elderly, has greatly increased the risk of drug-induced liver injury (DILI) in general, and drug-induced fatty liver disease (DIFLD) in particular. This review focuses on the contribution of DIFLD to DILI in terms of epidemiology, pathophysiology, the most common drugs associated with DIFLD, and treatment strategies.
ISSN:2225-0719
2310-8819
DOI:10.14218/JCTH.2020.00091